PT - JOURNAL ARTICLE AU - Amy L. Kennalley AU - John A. Furst, Jr. AU - Nicholas J. Mynarski AU - Kenneth L. McCall AU - Brian J. Piper TI - Methadone Distribution Increased from 2010 to 2019 for Opioid Use Disorder Treatment in the US AID - 10.1101/2022.03.09.22272154 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.09.22272154 4099 - http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272154.short 4100 - http://medrxiv.org/content/early/2022/03/12/2022.03.09.22272154.full AB - Objectives To identify US prescription trends in methadone distribution for OUD from 2010 to 2020.Methods The weight of methadone in grams distributed to OTPs per state was derived from the US Drug Enforcement Administration’s Automated Reports and Consolidated Ordering System. Methadone was adjusted for state population and compared across all fifty states and Washington DC from 2010 to 2020.Results The overall distribution of methadone to OTPs significantly (P < 0.0001) increased from 2010 to 2019 (+61.0%) and from 2015 to 2020 (+26.22%). The states with the highest percent change from 2010 to 2020 were Montana (+897.02%), Alaska (+421.11%), and Vermont (+353.67%). In contrast with prior increase of distribution, from 2019 (pre-COVID-19 pandemic) to 2020 (during pandemic), there was no significant change in the distribution of methadone to OTPs (-0.09%). Ohio (+26.02%) significantly increased while Alabama (-21.96%), New Hampshire (-24.13%) and Florida (-28.97%) significantly decreased methadone relative to the national mean.Conclusions This investigation revealed two trends related to methadone distribution in the US: increased utilization over the past decade and a plateau in utilization from 2019 to 2020. Policies are needed to remove access barriers to methadone treatment during the COVID-19 pandemic in order to reduce the worsening crisis of opioid overdoses in the US.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at the DEA's Automated Reports and Consolidated Ordering System. https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/index.html